FDA Issues Import Block On Eli Lilly's Cialis; Intrexon, ZIOPHARM, and MD Anderson in Exclusive CAR T Pact

Print E-mail
Tuesday, 13 January 2015 20:00
Below is a look at some of the headlines for companies that made news in the healthcare sector on January 13, 2015.
Read more...
 

AAA Fully Acquires Atreus Pharmaceuticals; Enrolls First Patient In A Phase I/II Clinical Trial For Its Key Diagnostic Candidate Annexin V-128 In Rheumatoid Arthritis And Ankylosing Spondylitis

Print E-mail
Friday, 09 January 2015 08:13

08 January 2015 – Advanced Accelerator Applications S.A. (“AAA” or “the Company”), an international specialist in Molecular Nuclear Medicine (MNM), announced today that it has acquired the remaining 49.9% of Atreus Pharmaceuticals Corporation, a development-stage biopharmaceutical company headquartered in Ottawa, Canada and focused on the development of proprietary molecular imaging products aimed at imaging apoptosis and necrosis based on Annexin V. Atreus Pharmaceuticals Corporation is now a fully owned AAA subsidiary and has been renamed AAA Canada.

Read more...
 

Provectus Biopharmaceuticals to Meet with FDA on Operational Aspects of PV-10 Phase 3 Melanoma Study with Aim to Maximize Speed of Enrollment

Print E-mail
Tuesday, 23 December 2014 01:02

KNOXVILLE, Tenn.--Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it will be meeting with the U.S. Food and Drug Administration (the “FDA”) to review certain operational aspects of the protocol for its planned phase 3 clinical trial of intralesional PV-10, its novel investigational drug for cancer, as a treatment for melanoma.

Read more...
 

PlasmaTech Biopharmaceuticals, Inc. Announces Pricing of $14,000,000 Public Offering and Listing on NASDAQ

Print E-mail
Saturday, 20 December 2014 00:26

DALLAS and NEW YORK--PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI, PTBIW), a biopharmaceutical company advancing patient care in critical areas, announced the pricing of an underwritten public offering of 3,500,000 shares of common stock, and warrants to purchase up to an aggregate 3,500,000 shares of common stock, at an offering price of $4.00 per share and $.01 per warrant.  

Read more...
 

The Bakken Invitation Announces 2014 Honorees: 10 Inspiring People Who Live On and Give On

Print E-mail
Monday, 08 December 2014 11:18
MINNEAPOLIS--Medtronic (NYSE: MDT) today announced the names of 10 people from around the world who will be honored as part of the Bakken Invitation, a global program launched in 2013 that celebrates and connects people who, with the help of medical technology, have overcome health challenges and are now making a difference in their communities.
Read more...
 

Pluristem and Hadassah Medical Center Will Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes

Print E-mail
Thursday, 04 December 2014 22:17

HAIFA, ISRAEL--Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PSTI), a leading developer of placenta-based cell therapy products, announced today that it has entered into a long-term collaboration agreement with Hadassah Medical Center in Jerusalem.

Read more...
 

CEL-SCI Quarterly Patient Enrollment in Its Head and Neck Cancer Phase III Trial Increases Eight Fold Over Same Prior Year Period

Print E-mail
Tuesday, 02 December 2014 18:51
Vienna, VA--CEL-SCI Corporation (NYSE MKT: CVM) today announced  that during the past three months it has enrolled 58 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection). 
Read more...
 

Actinium Receives Orphan-Drug Designation from FDA for Actimab-A in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients

Print E-mail
Monday, 01 December 2014 18:45

NEW YORK, NY--Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the US Food and Drug Administration (FDA) has granted orphan-drug designation for Actimab-A, an alpha radiolabeled antibody being developed for newly diagnosed AML in patients over the age of 60. Actimab-A is currently in a multicenter Phase 1/2 trial clinical trial.

Read more...
 

Follow up on Purdue's approval of Hysingla - Relmada Therapeutics

Print E-mail
Thursday, 20 November 2014 20:19

New York-based Relmada Therapeutics (RLMD) has reinvented four proven and promising drug candidates with novel delivery systems to create new drugs for new indications.

Read more...
 

RELMADA THERAPEUTICS APPOINTS MICHAEL BECKER AS SENIOR VICE PRESIDENT OF FINANCE AND CORPORATE DEVELOPMENT

Print E-mail
Tuesday, 04 November 2014 19:51

New York, NY--Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has appointed Michael D. Becker as senior vice president of finance and corporate development, effective immediately.

Read more...
 
<< Start < Prev 1 3 > End >>

Page 1 of 3

News and Analysis

More News

Newsletter

BioMedReports Intercept Pharmaceuticals Soars 20%, Possible Short Squeeze; Vital Therapies Announces VTI-208 Phase 3 Clinica... http://t.co/z5VijOSfkl
7hreplyretweetfavorite
BioMedReports Baird Releases Comments After Vertex Earnings Call; Axxess to Expand North American Sales and Brand Exposure T... http://t.co/B8tKsZ5WFh
BioMedReports The Small-Cap Biotech Watchlist 2015 Unwrapped: Who Are These Guys? And Why Are They Here?: At the Biotech Sho... http://t.co/NbnlP66Mut